argenx SE Stock News

Argenx's flagship autoimmune drug hit the primary endpoint in a registrational trial for a progressive nerve disorder. Investors are cheering the news today.

Argenx (NASDAQ: ARGX ) stock is climbing higher on Monday following the release of data from a Phase 1 clinical trial. The company released results from its ADHERE study of VYVGART Hytrulo in adults

After recovering from COVID-19 infections, many people enter an extended period during which they suffer from a catalog of additional serious symptoms. It is estimated that at least 65 million people

argenx's Vyvgart Hytrulo, a game-changer with its 1-minute SC formulation, opens a new revenue stream for Halozyme with sales expected to surpass $10Bn. Despite past headwinds, Vyvgart's SC approval a

China's National Medical Products Administration (NMPA) has approved Zai Lab Limited's and Argenx SE's Biologics License Application (BLA) for VYVGART, a treatment for generalised myasthenia gravis (g

The U.S. Food and Drug Administration has approved Argenx SE's under-the-skin injection for the treatment of a muscle-weakening genetic disease called generalized myasthenia gravis, the company said o

May 3 1 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, toda

Argenx could have "one of the biggest biologics of all time," the biotech company contends. Argenx stock now trades at a record high.

argenex SE (ARGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

argenx SE (NASDAQ:ARGX ) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwerm

May 2 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today

April 27 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, tod

Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indi

Avoro Capital Advisors (formerly known as venBio Select Advisor) is a global life sciences investment firm that focuses on emerging biotechnology companies.

argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 4 0 0 0 Last 30D 1 0 0